Axicabtagene Ciloleucel
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Ruijin HospitalCell therapyPhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 65/ 100
- Competitive Position
- 89/ 100
Competitive context
270 Active assets in the Diffuse Large B-Cell Lymphoma, Not Otherwise Specified cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE National Cancer Institute (NCI) | Phase 2/3 | A |
Evomela Ruijin Hospital | Phase 4 | BBB |
FILGRASTIM Ruijin Hospital | Phase 3 | BBB |
Inno-206 Beth Israel Deaconess Medical Center | Phase 4 | BBB |
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Axicabtagene Ciloleucel is also rated in:
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaDormant
BBB
Indicative ·
77 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →